Advancements in the Management of Ovarian Cancer - Episode 2
Role of Genomic Instability Scores in Treatment Selection
Panelists discuss how genomic instability scores, including HRD vs HRP profiles, influence treatment selection and sequencing in ovarian cancer, particularly in guiding the use of PARP inhibitors and other targeted therapies in the maintenance setting, and how these scores may prompt adjustments to standard treatment approaches.
Video content above is prompted by the following:
1. Dr Chan to ask Dr Herzog: How do genomic instability scores influence treatment selection and sequencing in ovarian cancer, particularly for patients with HRD vs HRP profiles?
- In what ways do these scores guide the use of PARP inhibitors or other targeted therapies in the maintenance setting?
- Are there scenarios where genomic instability scores might lead you to modify your standard approach to treatment?
2. Dr Herzog to ask Dr Chan: Please comment on any challenges when treating the HRP patient population
Related Content:
